10x Genomics (TXG) Payables (2018 - 2026)

10x Genomics (TXG) has 9 years of Payables data on file, last reported at $17.4 million in Q1 2026.

• For the quarter ending Q1 2026, Payables rose 73.07% year-over-year to $17.4 million; the trailing twelve-month figure through Mar 2026 stood at $17.4 million (up 73.07% YoY), and the FY2025 full-year result was $12.7 million, down 1.36% from the prior year.
• Payables grew to $17.4 million in Q1 2026, from $12.7 million in the prior quarter.
• In the past five years, Payables ranged from a high of $29.3 million in Q1 2023 to a low of $10.1 million in Q1 2025.
• A 5-year average of $19.5 million and a median of $19.0 million in 2022 frame the typical range for Payables.
• Across the five-year window, Payables slumped 50.2% in 2025 and soared 73.07% in 2026, its largest moves.
• Tracing TXG's Payables over 5 years: stood at $21.6 million in 2022, then declined by 27.14% to $15.7 million in 2023, then dropped by 17.98% to $12.9 million in 2024, then fell by 1.36% to $12.7 million in 2025, then soared by 36.85% to $17.4 million in 2026.
• Business Quant data shows TXG's Payables at $17.4 million in Q1 2026, $12.7 million in Q4 2025, and $18.1 million in Q3 2025.